AI leverage meets new FDA risk
- Q1 2026 revenue rose 47% year over year, showing that demand is still strong.
- Gross margin expanded by 400 basis points in Q1 2026 as AI helped the care team and supply chain work faster.
- Management raised full-year 2026 revenue outlook to $798 million to $804 million.
- About 80% of contracted lives are now on engagement-based pricing, which can make near-term revenue harder to predict.
- The FDA has asked questions about TrueMotion, the company’s core AI motion tracking technology.
Fast growth, sharper questions
Hinge Health is proving that digital physical therapy can scale. Q1 2026 revenue grew 47% from the prior year, and gross margin rose by 400 basis points. Management says the margin gain came from better care team and supply chain efficiency, helped by internal AI tools.
The bull case is simple. Hinge sells to employers, health plans, and government plans that want to cut muscle and joint care costs. If AI keeps lowering the hours needed from human clinicians, revenue can grow much faster than costs.
The bear case has changed. State telehealth rules still matter, but the Illinois issue eased after a 2025 law change. Now the bigger worries are a stronger Sword and Kaia rival, the FDA inquiry into TrueMotion, and whether new pricing creates revenue misses.
The next year should answer several key questions. Watch HingeSelect adoption, the Migraine Care Program launch, the FDA TrueMotion process, and whether Hinge can hold share while the digital MSK market combines.
Employers pay when members engage
Hinge runs a B2B2C model. That means it sells to businesses and health plans, then delivers care to the people covered by those plans. Its main customers are self-insured employers, with more growth coming from fully-insured health plans, Medicare Advantage, and federal insurance plans.
The company sells annual subscriptions. Clients usually pay only after an eligible person uses the program in a billable way. Hinge then recognizes revenue over the member’s 12-month subscription period.
Pricing is shifting. About 80% of contracted lives are on engagement-based pricing, and the company is also moving some clients to an alternative engagement-based model. That can make revenue less predictable, especially if member use is different from what Hinge expects.
The model works best when Hinge keeps members active, proves savings to clients, and renews large contracts. It breaks if employers see weak engagement, if health plans push back on billing, or if regulators force changes to how care is delivered.
More than remote PT
Core MSK platform
This is the main business. It covers joint and muscle care, from new injuries to chronic pain to post-surgery rehab.
TrueMotion
TrueMotion uses AI-powered motion tracking to guide exercise and reduce the need for constant human review. It is central to Hinge’s scale advantage, but it is also the subject of an FDA information request.
Enso
Enso is an FDA-cleared wearable device for pain relief. It also supports newer programs like migraine care.
Robin
Robin is an always-on AI care assistant. Its job is to help members get support faster while lowering the workload on the care team.
HingeConnect
HingeConnect helps coordinate care and share real-time information for member support. It is part of the company’s effort to connect digital care with the outside health system.
HingeSelect
HingeSelect is an in-person provider network for MSK care. Management has said it does not expect much revenue impact until at least 2027, but it could become a moat if it scales well.
Women’s pelvic health and menopause
Hinge expanded women’s pelvic health and added a movement-based menopause program in 2025. These programs help widen the platform beyond standard physical therapy.
Migraine Care Program
The Migraine Care Program launched in May 2026 and uses Enso. Management said it had already been adopted by over 125 enterprise clients.
One platform, several buyers
For Q1 2026, Hinge disclosed subscription revenue from its platform and said it generates substantially all revenue in the United States. It does not disclose exact revenue shares by employer, health plan, Medicare Advantage, or federal channel.
What could go wrong
FDA TrueMotion review
High impact · Medium oddsThe FDA requested information about how Hinge markets TrueMotion and why the company believes it does not need FDA clearance or a prescription. If the FDA disagrees, Hinge may need to change labeling, seek clearance, slow product features, or face added costs. This matters because TrueMotion is part of the company’s AI scale story.
Pricing model surprise
Medium impact · Medium oddsHinge is moving more lives to engagement-based pricing, including a newer model that management says can be hard to predict. If members do fewer billable sessions than expected, revenue can come in lower even if the client count grows. This could also make quarterly results harder to read.
Sword and Kaia pressure
High impact · Medium oddsSword Health acquired Kaia Health in January 2026, creating a larger rival in digital MSK care. Bigger competitors can pressure prices, win employer bids, or copy features. Hinge must show that its AI, outcomes data, and partner access keep it ahead.
Telehealth and practice rules
Medium impact · Medium oddsHinge delivers care across state lines, where physical therapy, telehealth, and corporate practice of medicine rules can differ. Illinois risk eased in 2025 after a restrictive amendment was reversed, but other states can still create friction. More rules could raise costs or limit how care teams work.
HingeSelect execution
Medium impact · Medium oddsHingeSelect adds an in-person provider network to a digital-first model. It could deepen the moat, but it also adds provider oversight, quality control, and consumer protection risk. Management has said revenue impact is not expected to be meaningful until at least 2027.
In one breath
What does Hinge Health do?
Hinge Health provides digital care for muscle and joint problems, often called MSK care. Members use software, AI motion tracking, wearables, and support from licensed care teams.
Who pays Hinge Health?
Most revenue comes from self-insured employers. Hinge also sells through health plans, Medicare Advantage, and federal insurance plans.
Why is the FDA inquiry important?
TrueMotion is a core AI motion tracking tool for Hinge. If the FDA decides it needs clearance or a prescription, Hinge could face delays, added costs, or product changes.
Is Hinge Health profitable?
In Q1 2026, Hinge reported net income of $35.1 million on revenue of $182.3 million. The main investor question is whether that leverage can continue as competition and regulation get tougher.